Sun Pharmaceutical Industries Limited

Sun Pharma Advanced Research Company Limited

Bioprojet

Pharmaceutical Industries Limited

Rajamannar Thennati

Trinadha Rao Chitturi

Muthukumaran Natarajan

Subhas Balaram Bhowmick

Nishith C Chaturvedi

Ravishankara Madavati Nagaraja

Rishit Mansukhlal Zalawadia

Vipulkumar Shankarbhai Patel

Kunal Pandya

Brijeshkumar Patel

Dhiren Rameshchandra Joshi

Krunal Harishbhai Soni

Abhishek Tiwari

Pradeep Dinesh Shahi

Vinod Sampatrao Burade

Sudeep Kumar Agrawal

Kanaksinh Jesingbhai Jadav

Srinivasu Kilaru

Shirish Kulkarni

Nileshkumar Sureshbhai Patel

Vimal Kaneria

Gaurav Sanjivkumar Sheth

Rajeev Budhdev Rehani

Jiten Ranchhodbhai Patel

Gopalkumar Chimanlal Patel

Alpesh Goyani

Deepak Singodia

Amol Kulkarni

Mukesh Sharma

Bhaskar Pallerla

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Marc Capet

Philippe Robert

Isabelle Berrebi-Bertrand

Jayraj Dilipbhai Aradhye

Bhavesh Mohanbhai Panchal

Ranjan Kumar Pal

Biswajit Samanta

Amar Rana

Hemant Ashvinbhai Chokshi

Rakesh Thummar

Hetalkumar Virendrabhai Patel

Prashant Kane

Samarth Kumar

Nicolas Levoin

Harshal Jahagirdar

Ajay Sohanlal Midha

Sanjay Nandlal Mandhane

Muthukumaran Natarajan Pillai

Prabal Sengupta

Sonny Sebastian

Sabbirhusen Yusufbhai Chimanwala

Milan Mohanbhai Vasoya

Japan Nitinkumar Desai

Sandeep Pankajbhai Pathak

Keshav Deo

Vijay Chhangamal Chhabada

Varun Anilkumar Mehta

Chitturi Trinadha Rao

Nischal Vinodbhai Patel

Vijay Muljihhai Patel

Shivramchandra Kanangi

Raja Sekhar Unnam

Macwan Valance Surendrakumar

Mehul Chandrakatbhai Bhatt

Kartik Shantilal Patel

Tilak Chandra

Hemant Ashvinbhai Shah

Raja Jyotir Jani

Vijaykumar Muljibhai Patel

Hetal Virendra Patel

Sudhakar Kambhampati

Ashok Punju Borase

Kamleshkumar Naranbhai Borkhataria

Soni Maheshkumar Parasmal

Sanjay Poptani

T Nathamani

Dwivedi Shriprakash Dhar

Mukesh Nathalal Vaghela

Rashminkumar Rameshchandra Pandya

Dijixa Chandubhai Rana

Kaushik Dhanjubhai Prajapati

Rajendrasinh Rathod

Tushar Bhatt

Kiritkumar Joshi

Binaka Dole

Kadiyala V S N Murty

Chetan Surjitsingh Puri

Dipali Manubhai Desai

Jignesh Kantilal Jivani

Samir Rameshchandra Shah

Rutvij Manharlal Bhatt

Mandakini Muthukumaran

Jaydip Joshi

Jonathan David Atkinson

Bhavesh M Panchal

Jayraj D Aradhye

Bhushan Jadhav

Kadiyala VSN Murty

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

GLP-1 analogues

A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25&#xb0; C. and 60% relative humidity for at least three months.

Parenteral unit dosage form of dihydroergotamine

A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25&#xb0; C. and 60% relative humidity for at least three months. 

The present invention provides a stable, aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base. The invention also provides a method of treating the septic shock by intravenous administration of stable aqueous injectable solution comprising epinephrine or its pharmaceutically acceptable salt, a sulfite antioxidant, butylated hydroxyl anisole, an organic acid and a chelating agent, wherein the solution is free of an inorganic acid and an inorganic base.

Stable aqueous injectable solution of epinephrine

The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.

Parenteral dosage form of amiodarone

The present invention relates to a sterile solution comprising: octreotide in the form of a pharmaceutically acceptable salt, present at a concentration equivalent to 2.0 mg/ml to 2.5 mg/ml of octreotide base, and at least one preservative in a pharmaceutically acceptable vehicle, wherein the sterile solution is present in an injection device.

Octreotide injection

A method of stabilizing linaclotide in a solid dosage form, said method comprising

Linaclotide stable composition

The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.

Oral pharmaceutical dosage forms of budesonide

The present invention provides novel salts of nilotinib and polymorphs thereof. The acid addition salts of nilotinib with benzenesulfonic acid, butanedisulfonic acid, 1-5-naphthalenedisulfonic acid, naphthalene-1-sulfonic acid and 1-hydroxynaph-thoic acid; hydrates and anhydrates thereof.

Salts of nilotinib and polymorphs thereof

Growing community of inventors

Baroda, India

Rajamannar Thennati